LONDON and WILMINGTON, N.C. -- Chiltern International Limited (Chiltern), a global contract research organization (CRO), announces the appointments of Dr Manuela Niewel and Lisa Bull to secure Chiltern's continued success and future growth.
Dr Manuela Niewel has been appointed Medical Director to serve as therapeutic expert in the oncology area in the medical department. Manuela is a medical oncologist with more than 20 years experience in clinical research in oncology and other major therapeutic areas. Manuela is field-based in Munich, Germany.
"I am extremely pleased to have Manuela's strong expertise in our medical department as it will provide our clients with a broader oncology experience to help them overcome the complexities often found in oncology trials. In previous roles, Manuela served as Senior Medical Director where she was responsible for Phase I-III oncology trials and has led clinical research teams for both pharmaceutical and clinical research companies. In addition to her medical qualification, Manuela holds a diploma in Pharmaceutical Medicine and is a member of the American Society of Clinical Oncology, the American Association of Clinical Research, the European Society of Medical Oncology and the German Society of Cancer," stated Aize Smink, Chief Operating Officer.
Lisa Bull has been appointed Director of Strategic Partnerships in the Business Development function and joins Chiltern with more than 20 years experience in the pharmaceutical and CRO industries. Lisa is field-based in the UK and a holds a BA (Hons) degree in Business Studies from UK's Westminster University.
Stuart McGuire , VP, Global Business Development, said: "It gives me great pleasure to welcome Lisa Bull as Director of Strategic Partnerships. Lisa's appointment reflects our ongoing commitment to building on Chiltern's current success by investing in growth, developing new services and deepening our strategic relationships with existing clients. Lisa has a thorough understanding of clinical development in multiple therapeutic areas and geographies, as well as a strong track record in establishing long standing and successful partnerships."
Established in 1982, Chiltern is a leading global clinical CRO with extensive experience in the management of Phase I-IV clinical trials across a broad range of therapeutic areas, functional service provision and contract staffing solutions. Chiltern has conducted trials in more than 40 countries, employs more than 1,500 people globally and offers services in Early Phase, Global Clinical Development, Late Phase, Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Chiltern prides itself as a development partner that offers flexibility, responsiveness and quality delivery. Further information is available at: www.chiltern.com.